InMed $IN on the Front Lines of Cannabinoid Biosynthesis

InMed Pharma(CSE: IN, OTCQB: IMLFF)

InMed Pharmaceuticals Inc.  has released today an update on its proprietary research into synthesizing cannabinoids for use as pharmaceuticals. The Company has successfully demonstrated the capacity to reproduce any and all of the more than  90 cannabinoids through its biosynthesis process.

InMed has become the first company to be able to synthesize the full active complex of the cannabinoid, including precursors, enzymes, and synthases via the use of the E.coli bacteria. This is a very similar process to how insulin is synthesized for the treatment of diabetes, and is less-expensive and time-consuming than any extraction process.

The Company plans several new pilot studies to further advance these initiatives and is supporting its research through continuing to generate new patents.